Literature DB >> 18208898

Natural history of secondary-progressive multiple sclerosis.

Helen Tremlett1, Virginia Devonshire.   

Abstract

OBJECTIVE: To examine prognosis and risk factors for progression to and from secondary-progressive multiple sclerosis (SPMS).
METHODS: Patients with definite relapsing-remitting MS (RRMS), onset before July 1988, attending a British-Columbian MS clinic before July 1998, and at least one Expanded Disability Status Scale (EDSS) scores were selected from the population-based database. Time to SPMS (from onset and birth) and the subsequent time to EDSS 8 were examined, as were potential risk factors.
RESULTS: In all, 2484/2837 (87.6%) were relapsing-remitting (RR) at onset, with 1445/2484 (58.2%) reaching SPMS, taking a median 18.9 years (95% CI: 18.2-19.7). Those younger at onset took longer to reach SPMS (P < 0.0005), but did so at a younger age (P < 0.0005). Males reached SPMS more rapidly from onset and at a younger age (P < 0.0005), but were around the same age as females at EDSS 8 (P = 0.975). Characteristics at SPMS onset associated with a longer time from SPMS to EDSS 8 and an older age at EDSS 8 were: longer disease duration (P < 0.02), older age (P < 0.01) and lower EDSS (P < 0.0005). Onset symptoms had little influence on time to SPMS or subsequent progression.
CONCLUSIONS: The RR phase lasted on average almost two decades, being shorter for males and those older at onset of MS. However, neither were necessarily unfavorable predictors as those older at onset were typically older at SPMS and eventually males and females reached EDSS 8 at around the same age. A longer RR phase was a favorable predictor of disease progression in SPMS. Furthermore, reaching SPMS at an older age or lower EDSS did not necessarily confer a worse outcome.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18208898     DOI: 10.1177/1352458507084264

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  43 in total

1.  Magnetic resonance monitoring of lesion evolution in multiple sclerosis.

Authors:  Alex Rovira; Cristina Auger; Juli Alonso
Journal:  Ther Adv Neurol Disord       Date:  2013-09       Impact factor: 6.570

2.  Impact of multiple sclerosis relapses on progression diminishes with time.

Authors:  H Tremlett; M Yousefi; V Devonshire; P Rieckmann; Y Zhao
Journal:  Neurology       Date:  2009-11-04       Impact factor: 9.910

3.  Modeling Approaches in Cost-Effectiveness Analysis of Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: An Updated Systematic Review and Recommendations for Future Economic Evaluations.

Authors:  Luis Hernandez; Malinda O'Donnell; Maarten Postma
Journal:  Pharmacoeconomics       Date:  2018-10       Impact factor: 4.981

Review 4.  Differential diagnosis of Mendelian and mitochondrial disorders in patients with suspected multiple sclerosis.

Authors:  James D Weisfeld-Adams; Ilana B Katz Sand; Justin M Honce; Fred D Lublin
Journal:  Brain       Date:  2015-01-29       Impact factor: 13.501

Review 5.  The role of glial-neuronal metabolic cooperation in modulating progression of multiple sclerosis and neuropathic pain.

Authors:  Rachel R Robinson; Alina K Dietz; Asif M Maroof; Reto Asmis; Thomas G Forsthuber
Journal:  Immunotherapy       Date:  2019-02       Impact factor: 4.196

6.  A potent and selective C-11 labeled PET tracer for imaging sphingosine-1-phosphate receptor 2 in the CNS demonstrates sexually dimorphic expression.

Authors:  Xuyi Yue; Hongjun Jin; Hui Liu; Adam J Rosenberg; Robyn S Klein; Zhude Tu
Journal:  Org Biomol Chem       Date:  2015-06-25       Impact factor: 3.876

Review 7.  [Multiple sclerosis : rehabilitation and long-term course].

Authors:  S Beer; J Kesselring
Journal:  Ophthalmologe       Date:  2014-08       Impact factor: 1.059

8.  The outcome spectrum of multiple sclerosis: disability, mortality, and a cluster of predictors from onset.

Authors:  Helen Tedeholm; Bengt Skoog; Vera Lisovskaja; Björn Runmarker; Olle Nerman; Oluf Andersen
Journal:  J Neurol       Date:  2015-02-26       Impact factor: 4.849

9.  Thyroid hormone alleviates demyelination induced by cuprizone through its role in remyelination during the remission period.

Authors:  Mao Zhang; Xiao L Zhan; Zi Y Ma; Xing S Chen; Qi Y Cai; Zhong X Yao
Journal:  Exp Biol Med (Maywood)       Date:  2015-01-10

10.  Long-standing multiple sclerosis neurodegeneration: volumetric magnetic resonance imaging comparison to Parkinson's disease, mild cognitive impairment, Alzheimer's disease, and elderly healthy controls.

Authors:  Dejan Jakimovski; Niels Bergsland; Michael G Dwyer; Jesper Hagemeier; Deepa P Ramasamy; Kinga Szigeti; Thomas Guttuso; David Lichter; David Hojnacki; Bianca Weinstock-Guttman; Ralph H B Benedict; Robert Zivadinov
Journal:  Neurobiol Aging       Date:  2020-02-08       Impact factor: 4.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.